Where AI creates real value in drug discovery and clinical trials

# Where AI creates real value in drug discovery and clinical trials

In 2020, an MIT-affiliated team used a deep learning model to screen over 100 million molecular compounds and identified halicin, a compound with structure unlike any known antibiotic, effective against drug-resistant bacteria including strains resistant to every antibiotic tested. The screening took days. A conventional wet-lab approach would have taken years. That is the promise of AI in pharma. The problem: most AI pilots in this industry never reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → that kind of outcome. They stall in what practitioners call "pilot purgatory," proof-of-concepts that never scale into production.

This lesson gives you a framework to tell the difference: where AI is delivering measurable value today, and where it's still speculative.

The value chain: four zones of AI application

Drug development runs roughly through four stages. AI's maturity differs sharply across them.

1. Target discovery and molecule design. This is where AI has the strongest evidence base. Models predict protein structures, screen candidate molecules computationally, and flag promising leads before a single compound is synthesized. DeepMind's AlphaFold, which predicts 3D protein structure from amino acid sequence, is the landmark case: it made structures for nearly all cataloged proteins freely available via the AlphaFold Protein Structure Database, collapsing a process that once took months of crystallography into minutes of computation.

2. Preclinical development. AI-assisted toxicity prediction and drug-repurposing (finding new uses for existing approved drugs) show real but more mixed results. Existing drugs already have safety data, so AI-driven repurposing shortens the riskiest part of development. Success stories exist, but validation rates are inconsistent across disease areas.

3. Clinical trials. This is the pilot purgatory zone. Patient recruitment, site selection, and trial design are being piloted by nearly every large pharma company, but few have publicly reported trial-level time or cost reductions verified by regulators.

4. Post-market and commercial. Pharmacovigilance (the science of detecting and monitoring adverse drug effects) increasingly uses natural language processing to scan medical literature, social media, and call center transcripts for safety signals. This is quietly one of the most operationally mature uses of AI in the sector, because the task, pattern detection in text and reports, plays to current AI strengths.

Case study 1: AMR antibiotic discovery, why it worked

Antimicrobial resistance (AMR) is when bacteria evolve to survive drugs designed to kill them. The World Health Organization (WHO) lists AMR as one of the top global public health threats. Traditional antibiotic discovery had stalled for decades: most major pharma companies exited the field because antibiotics are cheap, used briefly, and generate poor returns compared to chronic disease drugs.

The halicin case worked because of three conditions that generalize:

• A well-defined, computable problem. Predicting whether a molecule will inhibit bacterial growth is a task suited to supervised machine learning, given enough labeled training data (compounds tested and known to work or not).
• High-quality existing data. Researchers trained the model on a library of about 2,500 known molecules with measured antibacterial activity.
• A narrow, verifiable output. The model's predictions still required wet-lab validation. AI didn't replace experimentation, it prioritized which experiments were worth running.

This pattern (narrow prediction task, strong labeled data, human-verified output) is the template for where AI in drug discovery reliably adds value.

Case study 2: trial patient-matching, why it's harder

Clinical trial recruitment is chronically slow. Industry estimates commonly cited (treat as approximate) suggest roughly 80% of trials in the US miss enrollment deadlines, and the ClinicalTrials.gov registry shows thousands of trials terminated early for insufficient enrollment.

AI matching tools promise to scan electronic health records (EHR) and match eligible patients to trial criteria automatically. Companies like IQVIA, Tempus, and various hospital-embedded startups offer this. The logic is sound. The execution is hard, because:

• EHR data is messy. Fields are inconsistently coded across hospital systems; trial eligibility criteria are written in dense clinical language that models must parse correctly.
• Interoperability barriers. In the US, EHR systems (Epic, Cerner/Oracle Health) often don't share data cleanly across institutions, limiting a matching tool's reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → to whatever system it's plugged into.
• Regulatory and privacy constraints. Patient data use is governed by HIPAA (Health Insurance Portability and Accountability Act) in the US and GDPR (General Data Protection Regulation) in Europe, both of which restrict how identifiable health data can be used to train or run matching algorithms without consent frameworks.
• The output is probabilistic, not final. Even a good match still requires a clinician to confirm eligibility, informed consent, and site capacity. AI shortens a search step in a process that has many non-AI bottlenecks.

The lesson: patient-matching AI works well as a decision-support tool (ranking candidates for a human recruiter to review) but underdelivers when marketed as an end-to-end automation solution. This is the classic purgatory pattern: real efficiency gain at one narrow step, oversold as a systemic fix.

A simple framework for evaluating any pharma AI pitch

When assessing a vendor claim or internal pilot, ask:

1. Is the task narrow and well-labeled? (Molecule toxicity prediction: yes. "Optimize the whole trial": no.)

2. Is there a human verification step before high-stakes action? If not, regulatory risk is high.

3. What's the data source, and is it representative? A model trained mostly on US academic hospital data may perform worse on rural or non-US populations, a real generalization risk regulators increasingly scrutinize.

4. Has it been validated against a real outcome, not just a proxy metric? A model that predicts "trial matches found" is not the same as one that predicts "patients enrolled and retained."

5. What does the regulator say? The FDA (US Food and Drug Administration) has issued draft guidance on AI/ML use in drug development, and the EMA (European Medicines Agency) has a parallel reflection paper on AI in the medicinal product lifecycle. Neither has full binding frameworks yet for most use cases, which itself is a signal: expect slower adoption in regulated, high-stakes decision points until standards mature.

A quick illustrative calculation on ROIROIReturn on Investment: the ratio of net profit to the cost of an investment. A 300% ROI means each dollar invested returns $3.View full definition → framing (using illustrative, rounded figures, not vendor-specific data): if a mid-size trial costs an estimated $30 million and a patient-matching tool cuts recruitment time by even 10%, on a trial with a 2-year recruitment window, that's roughly 2.4 months saved. At an estimated industry figure of $600,000-$800,000 per day of trial delay cost (commonly cited estimate, varies widely by therapeutic area), that 2.4-month acceleration could represent tens of millions in avoided delay cost, even before counting faster patient access. This is why even modest, well-scoped AI gains in trials are commercially significant, despite the sector's overall slow adoption curve.

Where the puppet strings are: real market players

• DeepMind / Isomorphic Labs (Alphabet): protein structure and molecule design, partnering with pharma majors including Eli Lilly and Novartis.
• Insilico Medicine: AI-generated drug candidates, notably a fibrosis drug candidate that reached human trials, an early proof that AI-designed molecules can clear regulatory entry points.
• IQVIA, Tempus, Medidata (Dassault Systèmes): trial operations, patient data, and recruitment support tools used widely by large pharma sponsors.
• Regulators: FDA and EMA are the two bodies to watch. Their evolving stances directly gate what AI applications can move from pilot to standard practice, especially anything touching diagnosis, dosing, or trial endpoint determination.

Key Takeaways

• AI delivers the most verified value in narrow, well-labeled prediction tasks with a human verification step: molecule screening, protein structure prediction, toxicity flagging, and pharmacovigilance text mining.